Liz Highleyman

Dr. W. Kimryn Rathmell of Vanderbilt University Medical Center is a renowned kidney cancer expert.

Both approaches may offer a nonpharmaceutical option to use instead of or alongside opioids pain medication.

MASLD and MASH can lead to liver fibrosis, cirrhosis and liver cancer.

However, only 24% of people with hepatocellular carcinoma received direct-acting antiviral therapy.

An increase in fatty liver disease could double liver cancer cases and nearly triple the need for transplants by 2050.

Name change emphasizes the role of metabolic dysfunction in fatty liver disease.

Bertagnolli is committed to making clinical trials faster, more inclusive and more responsive.

Adding checkpoint inhibitors to chemotherapy before surgery and continuing them alone afterward reduces the risk of recurrence and death.

The radiopharmaceutical doubled progression-free survival time from six to 12 months.

People who received the targeted therapy after surgery were less likely to experience recurrence or brain metastasis.

A chemotherapy-free regimen combining immunotherapy with an antibody-drug conjugate extended survival by 15 months.

Two of 11 people who received four doses of budigalimab maintained viral suppression for a year and a half after stopping antiretrovirals.

Topical treatment may be as effective as electrocautery for anal neoplasia but with fewer adverse effects.

The checkpoint inhibitor is now indicated for pre- and post-surgery treatment of Stage II or III non-small-cell lung cancer.

Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.